Related references
Note: Only part of the references are listed.T peripheral helper cells in autoimmune diseases
Kathryne E. Marks et al.
IMMUNOLOGICAL REVIEWS (2022)
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Emily K. Sims et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Characteristics of children diagnosed with type 1 diabetes before vs after 6 years of age in the TEDDY cohort study
Jeffrey P. Krischer et al.
DIABETOLOGIA (2021)
Immunotherapy: Building a bridge to a cure for type 1 diabetes
Jeffrey A. Bluestone et al.
SCIENCE (2021)
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes
Manuela Battaglia et al.
DIABETES CARE (2020)
Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes
Natalie M. Edner et al.
NATURE IMMUNOLOGY (2020)
Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis
Majid Mobasseri et al.
HEALTH PROMOTION PERSPECTIVES (2020)
Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes
Peter S. Linsley et al.
GENES AND IMMUNITY (2019)
Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance
Simon Glatigny et al.
JOURNAL OF IMMUNOLOGY (2019)
Circulating CXCR5-PD-1hi peripheral T helper cells are associated with progression to type 1 diabetes
Ilse Ekman et al.
DIABETOLOGIA (2019)
Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019
William T. Cefalu et al.
DIABETES CARE (2019)
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018
Nicole C. Foster et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes
Polly J. Bingley et al.
DIABETES CARE (2018)
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study
Araz Rawshani et al.
LANCET (2018)
Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes A Randomized Clinical Trial
C. Greenbaum et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease
Marcela Herrera et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2017)
Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association
Richard A. Insel et al.
DIABETES CARE (2015)
Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
Tihamer Orban et al.
DIABETES CARE (2014)
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
Tihamer Orban et al.
LANCET (2011)
ICOS mediates the development of insulin-dependent diabetes mellitus in nonobese diabetic mice
Daniel Hawiger et al.
JOURNAL OF IMMUNOLOGY (2008)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept - Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial
JM Kremer et al.
ARTHRITIS AND RHEUMATISM (2005)
CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen
LSK Walker et al.
JOURNAL OF IMMUNOLOGY (2002)
Share Paper
